Infective Endocarditis Caused by Staphylococcus aureus After Transcatheter Aortic Valve Replacement

David del Val; Mohamed Abdel-Wahab; Norman Mangner; Eric Durand; Nikolaj Ihlemann; Marina Urena; Costanza Pellegrini; Francesco Giannini; Tomasz Gasior; Wojtek Wojakowski; Martin Landt; Vincent Auffret; Jan Malte Sinning; Asim N. Cheema; Luis Nombela-Franco; Chekrallah Chamandi; Francisco Campelo-Parada; Erika Munoz-Garcia; Howard C. Herrmann; Luca Testa; Kim Won-Keun; Juan Carlos Castillo; Alberto Alperi; Didier Tchetche; Antonio L. Bartorelli; Samir Kapadia; Stefan Stortecky; Ignacio Amat-Santos; Harindra C. Wijeysundera; John Lisko; Enrique Gutiérrez-Ibanes; Vicenç Serra; Luisa Salido; Abdullah Alkhodair; Igor Vendramin; Tarun Chakravarty; Stamatios Lerakis; Victoria Vilalta; Ander Regueiro; Rafael Romaguera; Utz Kappert; Marco Barbanti; Jean Bernard Masson; Frédéric Maes; Claudia Fiorina; Antonio Miceli; Susheel Kodali; Henrique B. Ribeiro; Jose Armando Mangione; Fabio Sandoli de Brito; Guglielmo Mario Actis Dato; Francesco Rosato; Maria Cristina Ferreira; Valter Corriea de Lima; Alexandre Siciliano Colafranceschi; Alexandre Abizaid; Marcos Antonio Marino; Vinicius Esteves; Julio Andrea; Roger R. Godinho; Fernando Alfonso; Helene Eltchaninoff; Lars Søndergaard; Dominique Himbert; Oliver Husser; Azeem Latib; Hervé Le Breton; Clement Servoz; Isaac Pascual; Saif Siddiqui; Paolo Olivares; Rosana Hernandez-Antolin; John G. Webb; Sandro Sponga; Raj Makkar; Annapoorna S. Kini; Marouane Boukhris; Philippe Gervais; Axel Linke; Lisa Crusius; David Holzhey; Josep Rodés-Cabau

doi:10.1016/j.cjca.2021.10.004

Infective Endocarditis Caused by Staphylococcus aureus After Transcatheter Aortic Valve Replacement

David del Val, Mohamed Abdel-Wahab, Norman Mangner, Eric Durand, Nikolaj Ihlemann, Marina Urena, Costanza Pellegrini, Francesco Giannini, Tomasz Gasior, Wojtek Wojakowski, Martin Landt, Vincent Auffret, Jan Malte Sinning, Asim N. Cheema, Luis Nombela-Franco, Chekrallah Chamandi, Francisco Campelo-Parada, Erika Munoz-Garcia, Howard C. Herrmann, Luca TestaKim Won-Keun, Juan Carlos Castillo, Alberto Alperi, Didier Tchetche, Antonio L. Bartorelli, Samir Kapadia, Stefan Stortecky, Ignacio Amat-Santos, Harindra C. Wijeysundera, John Lisko, Enrique Gutiérrez-Ibanes, Vicenç Serra, Luisa Salido, Abdullah Alkhodair, Igor Vendramin, Tarun Chakravarty, Stamatios Lerakis, Victoria Vilalta, Ander Regueiro, Rafael Romaguera, Utz Kappert, Marco Barbanti, Jean Bernard Masson, Frédéric Maes, Claudia Fiorina, Antonio Miceli, Susheel Kodali, Henrique B. Ribeiro, Jose Armando Mangione, Fabio Sandoli de Brito, Guglielmo Mario Actis Dato, Francesco Rosato, Maria Cristina Ferreira, Valter Corriea de Lima, Alexandre Siciliano Colafranceschi, Alexandre Abizaid, Marcos Antonio Marino, Vinicius Esteves, Julio Andrea, Roger R. Godinho, Fernando Alfonso, Helene Eltchaninoff, Lars Søndergaard, Dominique Himbert, Oliver Husser, Azeem Latib, Hervé Le Breton, Clement Servoz, Isaac Pascual, Saif Siddiqui, Paolo Olivares, Rosana Hernandez-Antolin, John G. Webb, Sandro Sponga, Raj Makkar, Annapoorna S. Kini, Marouane Boukhris, Philippe Gervais, Axel Linke, Lisa Crusius, David Holzhey, Josep Rodés-Cabau

Medicine

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Background: Staphylococcus aureus (SA) has been extensively studied as causative microorganism of surgical prosthetic-valve infective endocarditis (IE). However, scarce evidence exists on SA IE after transcatheter aortic valve replacement (TAVR). Methods: Data were obtained from the Infectious Endocarditis After TAVR International Registry, including patients with definite IE after TAVR from 59 centres in 11 countries. Patients were divided into 2 groups according to microbiologic etiology: non-SA IE vs SA IE. Results: SA IE was identified in 141 patients out of 573 (24.6%), methicillin-sensitive SA in most cases (115/141, 81.6%). Self-expanding valves were more common than balloon-expandable valves in patients presenting with early SA IE. Major bleeding and sepsis complicating TAVR, neurologic symptoms or systemic embolism at admission, and IE with cardiac device involvement (other than the TAVR prosthesis) were associated with SA IE (P < 0.05 for all). Among patients with IE after TAVR, the likelihood of SA IE increased from 19% in the absence of those risk factors to 84.6% if ≥ 3 risk factors were present. In-hospital (47.8% vs 26.9%; P < 0.001) and 2-year (71.5% vs 49.6%; P < 0.001) mortality rates were higher among patients with SA IE vs non-SA IE. Surgery at the time of index SA IE episode was associated with lower mortality at follow-up compared with medical therapy alone (adjusted hazard ratio 0.46, 95% CI 0.22-0.96; P = 0.038). Conclusions: SA IE represented approximately 25% of IE cases after TAVR and was associated with very high in-hospital and late mortality. The presence of some features determined a higher likelihood of SA IE and could help to orientate early antibiotic regimen selection. Surgery at index SA IE was associated with improved outcomes, and its role should be evaluated in future studies.

Original language	English (US)
Pages (from-to)	102-112
Number of pages	11
Journal	Canadian Journal of Cardiology
Volume	38
Issue number	1
DOIs	https://doi.org/10.1016/j.cjca.2021.10.004
State	Published - Jan 2022

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.cjca.2021.10.004

Cite this

del Val, D., Abdel-Wahab, M., Mangner, N., Durand, E., Ihlemann, N., Urena, M., Pellegrini, C., Giannini, F., Gasior, T., Wojakowski, W., Landt, M., Auffret, V., Sinning, J. M., Cheema, A. N., Nombela-Franco, L., Chamandi, C., Campelo-Parada, F., Munoz-Garcia, E., Herrmann, H. C., ... Rodés-Cabau, J. (2022). Infective Endocarditis Caused by Staphylococcus aureus After Transcatheter Aortic Valve Replacement. Canadian Journal of Cardiology, 38(1), 102-112. https://doi.org/10.1016/j.cjca.2021.10.004

del Val, D, Abdel-Wahab, M, Mangner, N, Durand, E, Ihlemann, N, Urena, M, Pellegrini, C, Giannini, F, Gasior, T, Wojakowski, W, Landt, M, Auffret, V, Sinning, JM, Cheema, AN, Nombela-Franco, L, Chamandi, C, Campelo-Parada, F, Munoz-Garcia, E, Herrmann, HC, Testa, L, Won-Keun, K, Castillo, JC, Alperi, A, Tchetche, D, Bartorelli, AL, Kapadia, S, Stortecky, S, Amat-Santos, I, Wijeysundera, HC, Lisko, J, Gutiérrez-Ibanes, E, Serra, V, Salido, L, Alkhodair, A, Vendramin, I, Chakravarty, T, Lerakis, S, Vilalta, V, Regueiro, A, Romaguera, R, Kappert, U, Barbanti, M, Masson, JB, Maes, F, Fiorina, C, Miceli, A, Kodali, S, Ribeiro, HB, Mangione, JA, Sandoli de Brito, F, Actis Dato, GM, Rosato, F, Ferreira, MC, Corriea de Lima, V, Colafranceschi, AS, Abizaid, A, Marino, MA, Esteves, V, Andrea, J, Godinho, RR, Alfonso, F, Eltchaninoff, H, Søndergaard, L, Himbert, D, Husser, O, Latib, A, Le Breton, H, Servoz, C, Pascual, I, Siddiqui, S, Olivares, P, Hernandez-Antolin, R, Webb, JG, Sponga, S, Makkar, R, Kini, AS, Boukhris, M, Gervais, P, Linke, A, Crusius, L, Holzhey, D & Rodés-Cabau, J 2022, 'Infective Endocarditis Caused by Staphylococcus aureus After Transcatheter Aortic Valve Replacement', Canadian Journal of Cardiology, vol. 38, no. 1, pp. 102-112. https://doi.org/10.1016/j.cjca.2021.10.004

@article{5fe90519efb145e79b2de55c533ac6b9,

title = "Infective Endocarditis Caused by Staphylococcus aureus After Transcatheter Aortic Valve Replacement",

abstract = "Background: Staphylococcus aureus (SA) has been extensively studied as causative microorganism of surgical prosthetic-valve infective endocarditis (IE). However, scarce evidence exists on SA IE after transcatheter aortic valve replacement (TAVR). Methods: Data were obtained from the Infectious Endocarditis After TAVR International Registry, including patients with definite IE after TAVR from 59 centres in 11 countries. Patients were divided into 2 groups according to microbiologic etiology: non-SA IE vs SA IE. Results: SA IE was identified in 141 patients out of 573 (24.6%), methicillin-sensitive SA in most cases (115/141, 81.6%). Self-expanding valves were more common than balloon-expandable valves in patients presenting with early SA IE. Major bleeding and sepsis complicating TAVR, neurologic symptoms or systemic embolism at admission, and IE with cardiac device involvement (other than the TAVR prosthesis) were associated with SA IE (P < 0.05 for all). Among patients with IE after TAVR, the likelihood of SA IE increased from 19% in the absence of those risk factors to 84.6% if ≥ 3 risk factors were present. In-hospital (47.8% vs 26.9%; P < 0.001) and 2-year (71.5% vs 49.6%; P < 0.001) mortality rates were higher among patients with SA IE vs non-SA IE. Surgery at the time of index SA IE episode was associated with lower mortality at follow-up compared with medical therapy alone (adjusted hazard ratio 0.46, 95% CI 0.22-0.96; P = 0.038). Conclusions: SA IE represented approximately 25% of IE cases after TAVR and was associated with very high in-hospital and late mortality. The presence of some features determined a higher likelihood of SA IE and could help to orientate early antibiotic regimen selection. Surgery at index SA IE was associated with improved outcomes, and its role should be evaluated in future studies.",

author = "{del Val}, David and Mohamed Abdel-Wahab and Norman Mangner and Eric Durand and Nikolaj Ihlemann and Marina Urena and Costanza Pellegrini and Francesco Giannini and Tomasz Gasior and Wojtek Wojakowski and Martin Landt and Vincent Auffret and Sinning, {Jan Malte} and Cheema, {Asim N.} and Luis Nombela-Franco and Chekrallah Chamandi and Francisco Campelo-Parada and Erika Munoz-Garcia and Herrmann, {Howard C.} and Luca Testa and Kim Won-Keun and Castillo, {Juan Carlos} and Alberto Alperi and Didier Tchetche and Bartorelli, {Antonio L.} and Samir Kapadia and Stefan Stortecky and Ignacio Amat-Santos and Wijeysundera, {Harindra C.} and John Lisko and Enrique Guti{\'e}rrez-Ibanes and Vicen{\c c} Serra and Luisa Salido and Abdullah Alkhodair and Igor Vendramin and Tarun Chakravarty and Stamatios Lerakis and Victoria Vilalta and Ander Regueiro and Rafael Romaguera and Utz Kappert and Marco Barbanti and Masson, {Jean Bernard} and Fr{\'e}d{\'e}ric Maes and Claudia Fiorina and Antonio Miceli and Susheel Kodali and Ribeiro, {Henrique B.} and Mangione, {Jose Armando} and {Sandoli de Brito}, Fabio and {Actis Dato}, {Guglielmo Mario} and Francesco Rosato and Ferreira, {Maria Cristina} and {Corriea de Lima}, Valter and Colafranceschi, {Alexandre Siciliano} and Alexandre Abizaid and Marino, {Marcos Antonio} and Vinicius Esteves and Julio Andrea and Godinho, {Roger R.} and Fernando Alfonso and Helene Eltchaninoff and Lars S{\o}ndergaard and Dominique Himbert and Oliver Husser and Azeem Latib and {Le Breton}, Herv{\'e} and Clement Servoz and Isaac Pascual and Saif Siddiqui and Paolo Olivares and Rosana Hernandez-Antolin and Webb, {John G.} and Sandro Sponga and Raj Makkar and Kini, {Annapoorna S.} and Marouane Boukhris and Philippe Gervais and Axel Linke and Lisa Crusius and David Holzhey and Josep Rod{\'e}s-Cabau",

note = "Funding Information: Dr del Val was supported by a research grant from the Fundaci{\'o}n Alfonso Martin Escudero (Madrid, Spain). Dr Rod{\'e}s-Cabau holds the Research Chair “Fondation Famille Jacques Larivi{\`e}re” for the Development of Structural Heart Disease Interventions. The authors have no funding sources to declare. Dr Rod{\'e}s-Cabau has received institutional research grants from Edwards Lifesciences, Medtronic, and Boston Scientific. Dr Tchetche has reported consulting fees from Abbott Vascular, Boston Scientific, Edwards Lifesciences, and Medtronic. Dr Herrmann has received institutional research grants from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic and consulting fees from Edwards Lifesciences and Medtronic. Dr Webb has has received consulting fees from Edwards Lifesciences and St Jude Medical. Dr Makkar has received research grants from Edwards Lifesciences, Medtronic, Abbott, Capricor, and St Jude Medical, has served as a proctor for Edwards Lifesciences, and has received consulting fees from Medtronic. Dr de Brito has received honoraria from Medtronic and Edwards Lifesciences for symposium speeches and proctoring cases. Dr Lerakis has received consulting fees from Edwards Lifesciences. Dr Le Breton has received lecture fees from Edwards Lifesciences, outside the submitted work. Dr Sinning has received speaker honoraria from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic and research grants from Boston Scientific, Edwards Lifesciences, and Medtronic, outside the submitted work. Dr Won-Keun has received personal fees from Boston Scientific, Edwards Lifesciences, Abbott, Medtronic, and Meril, outside the submitted work. Dr Stortecky reports grants to his institution from Edwards Lifesciences, Medtronic, Boston Scientific, and Abbott and has received personal fees from Boston Scientific, BTG, and Teleflex, outside the submitted work. Dr Husser has received personal fees from Boston Scientific and payments from Abbott. Dr Mangner has received personal fees from Edwards Lifesciences, Medtronic, Biotronik, Novartis, Sanofi Genzyme, AstraZeneca, Pfizer, and Bayer, outside the submitted work. Dr Linke has received personal fees from Medtronic, Abbott, Edwards Lifesciences, Boston Scientific, Astra Zeneca, Novartis, Pfizer, Abiomed, Bayer, and Boehringer, outside the submitted work. The other authors have no conflicts of interest to disclose. Funding Information: Dr del Val was supported by a research grant from the Fundaci{\'o}n Alfonso Martin Escudero (Madrid, Spain). Dr Rod{\'e}s-Cabau holds the Research Chair “Fondation Famille Jacques Larivi{\`e}re” for the Development of Structural Heart Disease Interventions. Publisher Copyright: {\textcopyright} 2021 Canadian Cardiovascular Society",

year = "2022",

month = jan,

doi = "10.1016/j.cjca.2021.10.004",

language = "English (US)",

volume = "38",

pages = "102--112",

journal = "Canadian Journal of Cardiology",

issn = "0828-282X",

publisher = "Pulsus Group Inc.",

number = "1",

}

TY - JOUR

T1 - Infective Endocarditis Caused by Staphylococcus aureus After Transcatheter Aortic Valve Replacement

AU - del Val, David

AU - Abdel-Wahab, Mohamed

AU - Mangner, Norman

AU - Durand, Eric

AU - Ihlemann, Nikolaj

AU - Urena, Marina

AU - Pellegrini, Costanza

AU - Giannini, Francesco

AU - Gasior, Tomasz

AU - Wojakowski, Wojtek

AU - Landt, Martin

AU - Auffret, Vincent

AU - Sinning, Jan Malte

AU - Cheema, Asim N.

AU - Nombela-Franco, Luis

AU - Chamandi, Chekrallah

AU - Campelo-Parada, Francisco

AU - Munoz-Garcia, Erika

AU - Herrmann, Howard C.

AU - Testa, Luca

AU - Won-Keun, Kim

AU - Castillo, Juan Carlos

AU - Alperi, Alberto

AU - Tchetche, Didier

AU - Bartorelli, Antonio L.

AU - Kapadia, Samir

AU - Stortecky, Stefan

AU - Amat-Santos, Ignacio

AU - Wijeysundera, Harindra C.

AU - Lisko, John

AU - Gutiérrez-Ibanes, Enrique

AU - Serra, Vicenç

AU - Salido, Luisa

AU - Alkhodair, Abdullah

AU - Vendramin, Igor

AU - Chakravarty, Tarun

AU - Lerakis, Stamatios

AU - Vilalta, Victoria

AU - Regueiro, Ander

AU - Romaguera, Rafael

AU - Kappert, Utz

AU - Barbanti, Marco

AU - Masson, Jean Bernard

AU - Maes, Frédéric

AU - Fiorina, Claudia

AU - Miceli, Antonio

AU - Kodali, Susheel

AU - Ribeiro, Henrique B.

AU - Mangione, Jose Armando

AU - Sandoli de Brito, Fabio

AU - Actis Dato, Guglielmo Mario

AU - Rosato, Francesco

AU - Ferreira, Maria Cristina

AU - Corriea de Lima, Valter

AU - Colafranceschi, Alexandre Siciliano

AU - Abizaid, Alexandre

AU - Marino, Marcos Antonio

AU - Esteves, Vinicius

AU - Andrea, Julio

AU - Godinho, Roger R.

AU - Alfonso, Fernando

AU - Eltchaninoff, Helene

AU - Søndergaard, Lars

AU - Himbert, Dominique

AU - Husser, Oliver

AU - Latib, Azeem

AU - Le Breton, Hervé

AU - Servoz, Clement

AU - Pascual, Isaac

AU - Siddiqui, Saif

AU - Olivares, Paolo

AU - Hernandez-Antolin, Rosana

AU - Webb, John G.

AU - Sponga, Sandro

AU - Makkar, Raj

AU - Kini, Annapoorna S.

AU - Boukhris, Marouane

AU - Gervais, Philippe

AU - Linke, Axel

AU - Crusius, Lisa

AU - Holzhey, David

AU - Rodés-Cabau, Josep

N1 - Funding Information: Dr del Val was supported by a research grant from the Fundación Alfonso Martin Escudero (Madrid, Spain). Dr Rodés-Cabau holds the Research Chair “Fondation Famille Jacques Larivière” for the Development of Structural Heart Disease Interventions. The authors have no funding sources to declare. Dr Rodés-Cabau has received institutional research grants from Edwards Lifesciences, Medtronic, and Boston Scientific. Dr Tchetche has reported consulting fees from Abbott Vascular, Boston Scientific, Edwards Lifesciences, and Medtronic. Dr Herrmann has received institutional research grants from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic and consulting fees from Edwards Lifesciences and Medtronic. Dr Webb has has received consulting fees from Edwards Lifesciences and St Jude Medical. Dr Makkar has received research grants from Edwards Lifesciences, Medtronic, Abbott, Capricor, and St Jude Medical, has served as a proctor for Edwards Lifesciences, and has received consulting fees from Medtronic. Dr de Brito has received honoraria from Medtronic and Edwards Lifesciences for symposium speeches and proctoring cases. Dr Lerakis has received consulting fees from Edwards Lifesciences. Dr Le Breton has received lecture fees from Edwards Lifesciences, outside the submitted work. Dr Sinning has received speaker honoraria from Abbott, Boston Scientific, Edwards Lifesciences, and Medtronic and research grants from Boston Scientific, Edwards Lifesciences, and Medtronic, outside the submitted work. Dr Won-Keun has received personal fees from Boston Scientific, Edwards Lifesciences, Abbott, Medtronic, and Meril, outside the submitted work. Dr Stortecky reports grants to his institution from Edwards Lifesciences, Medtronic, Boston Scientific, and Abbott and has received personal fees from Boston Scientific, BTG, and Teleflex, outside the submitted work. Dr Husser has received personal fees from Boston Scientific and payments from Abbott. Dr Mangner has received personal fees from Edwards Lifesciences, Medtronic, Biotronik, Novartis, Sanofi Genzyme, AstraZeneca, Pfizer, and Bayer, outside the submitted work. Dr Linke has received personal fees from Medtronic, Abbott, Edwards Lifesciences, Boston Scientific, Astra Zeneca, Novartis, Pfizer, Abiomed, Bayer, and Boehringer, outside the submitted work. The other authors have no conflicts of interest to disclose. Funding Information: Dr del Val was supported by a research grant from the Fundación Alfonso Martin Escudero (Madrid, Spain). Dr Rodés-Cabau holds the Research Chair “Fondation Famille Jacques Larivière” for the Development of Structural Heart Disease Interventions. Publisher Copyright: © 2021 Canadian Cardiovascular Society

PY - 2022/1

Y1 - 2022/1

N2 - Background: Staphylococcus aureus (SA) has been extensively studied as causative microorganism of surgical prosthetic-valve infective endocarditis (IE). However, scarce evidence exists on SA IE after transcatheter aortic valve replacement (TAVR). Methods: Data were obtained from the Infectious Endocarditis After TAVR International Registry, including patients with definite IE after TAVR from 59 centres in 11 countries. Patients were divided into 2 groups according to microbiologic etiology: non-SA IE vs SA IE. Results: SA IE was identified in 141 patients out of 573 (24.6%), methicillin-sensitive SA in most cases (115/141, 81.6%). Self-expanding valves were more common than balloon-expandable valves in patients presenting with early SA IE. Major bleeding and sepsis complicating TAVR, neurologic symptoms or systemic embolism at admission, and IE with cardiac device involvement (other than the TAVR prosthesis) were associated with SA IE (P < 0.05 for all). Among patients with IE after TAVR, the likelihood of SA IE increased from 19% in the absence of those risk factors to 84.6% if ≥ 3 risk factors were present. In-hospital (47.8% vs 26.9%; P < 0.001) and 2-year (71.5% vs 49.6%; P < 0.001) mortality rates were higher among patients with SA IE vs non-SA IE. Surgery at the time of index SA IE episode was associated with lower mortality at follow-up compared with medical therapy alone (adjusted hazard ratio 0.46, 95% CI 0.22-0.96; P = 0.038). Conclusions: SA IE represented approximately 25% of IE cases after TAVR and was associated with very high in-hospital and late mortality. The presence of some features determined a higher likelihood of SA IE and could help to orientate early antibiotic regimen selection. Surgery at index SA IE was associated with improved outcomes, and its role should be evaluated in future studies.

AB - Background: Staphylococcus aureus (SA) has been extensively studied as causative microorganism of surgical prosthetic-valve infective endocarditis (IE). However, scarce evidence exists on SA IE after transcatheter aortic valve replacement (TAVR). Methods: Data were obtained from the Infectious Endocarditis After TAVR International Registry, including patients with definite IE after TAVR from 59 centres in 11 countries. Patients were divided into 2 groups according to microbiologic etiology: non-SA IE vs SA IE. Results: SA IE was identified in 141 patients out of 573 (24.6%), methicillin-sensitive SA in most cases (115/141, 81.6%). Self-expanding valves were more common than balloon-expandable valves in patients presenting with early SA IE. Major bleeding and sepsis complicating TAVR, neurologic symptoms or systemic embolism at admission, and IE with cardiac device involvement (other than the TAVR prosthesis) were associated with SA IE (P < 0.05 for all). Among patients with IE after TAVR, the likelihood of SA IE increased from 19% in the absence of those risk factors to 84.6% if ≥ 3 risk factors were present. In-hospital (47.8% vs 26.9%; P < 0.001) and 2-year (71.5% vs 49.6%; P < 0.001) mortality rates were higher among patients with SA IE vs non-SA IE. Surgery at the time of index SA IE episode was associated with lower mortality at follow-up compared with medical therapy alone (adjusted hazard ratio 0.46, 95% CI 0.22-0.96; P = 0.038). Conclusions: SA IE represented approximately 25% of IE cases after TAVR and was associated with very high in-hospital and late mortality. The presence of some features determined a higher likelihood of SA IE and could help to orientate early antibiotic regimen selection. Surgery at index SA IE was associated with improved outcomes, and its role should be evaluated in future studies.

UR - http://www.scopus.com/inward/record.url?scp=85122685546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122685546&partnerID=8YFLogxK

U2 - 10.1016/j.cjca.2021.10.004

DO - 10.1016/j.cjca.2021.10.004

M3 - Article

C2 - 34688853

AN - SCOPUS:85122685546

SN - 0828-282X

VL - 38

SP - 102

EP - 112

JO - Canadian Journal of Cardiology

JF - Canadian Journal of Cardiology

IS - 1

ER -

Infective Endocarditis Caused by Staphylococcus aureus After Transcatheter Aortic Valve Replacement

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this